European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Authors
Keywords
Acinetobacter baumannii, Carbapenem-resistant bacteria, ESCMID, GRADE, Multidrug resistant bacteria
Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-12-16
DOI
10.1016/j.cmi.2021.11.025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study
- (2021) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
- (2021) Tristan DELORY et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli
- (2021) Luigia Scudeller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)
- (2021) Adam G Stewart et al. Open Forum Infectious Diseases
- Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019
- (2020) E. Voulgari et al. Eurosurveillance
- Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
- (2020) Irene Galani et al. Eurosurveillance
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains
- (2020) Fatma Erdem et al. Antimicrobial Resistance and Infection Control
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
- (2020) Ivan Titov et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
- (2020) Gennaro De Pascale et al. Annals of Intensive Care
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- The clinical relevance of in vitro synergistic activity of antibiotics for MDR Gram-negative infections: A systematic review
- (2019) Konstantinos Z. Vardakas et al. Journal of Global Antimicrobial Resistance
- Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
- (2019) Tianshui Niu et al. Antimicrobial Resistance and Infection Control
- Once-Daily Plazomicin for Complicated Urinary Tract Infections
- (2019) Florian M.E. Wagenlehner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2019) James A. McKinnell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients
- (2019) Charles-Edouard Luyt et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae
- (2019) Maristela P. Freire et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: Alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam
- (2019) Hiroki Namikawa et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial
- (2019) Keith S Kaye et al. CLINICAL INFECTIOUS DISEASES
- Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
- (2019) Qiqiang Liang et al. Brazilian Journal of Infectious Diseases
- Non-intravenous carbapenem-sparing antibiotics for the definitive treatment of bacteremia due to Enterobacteriaceae-producing ESBL or AmpC β–lactamase. A propensity score study
- (2019) Yolanda Meije et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
- (2019) Stephan Göttig et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae
- (2019) Kalisvar Marimuthu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
- (2019) Basem M. Alraddadi et al. BMC INFECTIOUS DISEASES
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
- (2019) P. Zhang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase–producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis
- (2019) O. Senard et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016
- (2019) Tingting Xiao et al. Antimicrobial Resistance and Infection Control
- Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
- (2019) Chitra Punjabi et al. Open Forum Infectious Diseases
- Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant Enterobacteriaceae
- (2019) Cornelius J. Clancy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis
- (2019) Adrian Schmid et al. Scientific Reports
- Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?
- (2019) Sima L Sharara et al. CLINICAL INFECTIOUS DISEASES
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii
- (2018) T. Amat et al. CLINICAL MICROBIOLOGY AND INFECTION
- Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy
- (2018) G. Errico et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii
- (2018) C.-A. Liang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase–producing Enterobacteriaceae in an Italian Internal Medicine ward
- (2018) Simone Meini et al. European Journal of Internal Medicine
- Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection
- (2018) Maddalena Giannella et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae
- (2018) Se Ah Kim et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Association of high mortality with extended–spectrum β-lactamase (ESBL) positive cultures in community acquired infections
- (2018) Sumit Ray et al. JOURNAL OF CRITICAL CARE
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections
- (2018) Ting-Ting Geng et al. MEDICINE
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics
- (2018) Robin G. Otto et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Meropenem/colistin versus meropenem/ampicillin–sulbactam in the treatment of carbapenem-resistant pneumonia
- (2018) Hossein Khalili et al. Journal of Comparative Effectiveness Research
- Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
- (2018) Lindsay Petty et al. Infection and Drug Resistance
- Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial
- (2018) Yaakov Dickstein et al. CLINICAL INFECTIOUS DISEASES
- IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections
- (2018) Joseph S Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection
- (2018) Gregory Saraiva Medeiros et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM
- (2018) C. De la Calle et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
- (2018) Alessandro Cassini et al. LANCET INFECTIOUS DISEASES
- Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study
- (2018) F. Cancelli et al. Biomed Research International
- Colistin Monotherapy Versus Colistin and Rifampin Combination Therapy in Pneumonia Caused by Colistin-resistant Acinetobacter baumannii: A Randomized Controlled Trial
- (2018) Hye Jung Park et al. Journal of Global Antimicrobial Resistance
- Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: A nationwide multicenter study in Taiwan
- (2018) Yi-Tsung Lin et al. Open Forum Infectious Diseases
- The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2018) Courtney L Luterbach et al. Open Forum Infectious Diseases
- Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality
- (2017) M. Papadimitriou-Olivgeris et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study
- (2017) J.-H. Ko et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan
- (2017) Chin-Fang Su et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli
- (2017) Young Kyung Yoon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
- (2017) Juan J. Castón et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
- (2017) Matthew Sims et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
- (2017) Anna Both et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
- (2017) Evelyn Shaw et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
- (2017) Ching-Lung Lo et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
- (2017) Belén Gutiérrez-Gutiérrez et al. LANCET INFECTIOUS DISEASES
- Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae
- (2017) Yun Liao et al. Experimental and Therapeutic Medicine
- The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis
- (2017) Jian Wang et al. Annals of Clinical Microbiology and Antimicrobials
- Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial
- (2017) Joseph Solomkin et al. JAMA Surgery
- Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice
- (2017) Veena Venugopalan et al. Infectious Diseases
- Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia
- (2016) Ronen Zalts et al. AMERICAN JOURNAL OF THERAPEUTICS
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
- (2016) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
- (2016) A. Gomez-Simmonds et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model
- (2016) Cornelia B. Landersdorfer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome
- (2016) Claudia M. D. de Maio Carrilho et al. BMC INFECTIOUS DISEASES
- Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
- (2016) Takahiko Fukuchi et al. BMC INFECTIOUS DISEASES
- Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
- (2016) Jung-Jr Ye et al. BMC INFECTIOUS DISEASES
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia
- (2016) M.P. Freire et al. CLINICAL MICROBIOLOGY AND INFECTION
- Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae
- (2016) M. Falcone et al. CLINICAL MICROBIOLOGY AND INFECTION
- Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae
- (2016) A. Oliva et al. CLINICAL MICROBIOLOGY AND INFECTION
- Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases
- (2016) Polydoros Tofas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Synergistic combinations of polymyxins
- (2016) Justin R. Lenhard et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections
- (2016) Michael P. Veve et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
- (2016) Mervyn Singer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
- (2016) Oren Zusman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study
- (2016) Belén Gutiérrez-Gutiérrez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. MAYO CLINIC PROCEEDINGS
- Clinical Characteristics of Carbapenem-resistant Klebsiella pneumoniae Infections in Ill and Colonized Children in Colombia
- (2016) Alejandro Díaz et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam
- (2016) Murat DİZBAY et al. Turkish Journal Of Medical Sciences
- Infections due to Carbapenem Resistant Enterobacteriaceae among Saudi Arabian Hospitalized Patients: A Matched Case-Control Study
- (2016) M. A. Garbati et al. Biomed Research International
- Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-ProducingEnterobacteriaceaeBacteremia: Table 1.
- (2016) Ruibin Wang et al. Open Forum Infectious Diseases
- Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
- (2016) Maria Virginia Villegas et al. PLoS One
- Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
- (2016) Tat Ming Ng et al. PLoS One
- Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods
- (2015) Brian C. Nelson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
- (2015) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
- (2015) Nan-Yao Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- (2015) Romney M. Humphries et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia
- (2015) Yasufumi Matsumura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins
- (2015) M.S. de Oliveira et al. CLINICAL MICROBIOLOGY AND INFECTION
- Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia
- (2015) Aristine Cheng et al. CRITICAL CARE MEDICINE
- Hospital Readmissions in Patients With Carbapenem-Resistant Klebsiella pneumoniae
- (2015) Julia A. Messina et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study
- (2015) Chen-Hsiang Lee et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection
- (2015) Shujuan Ji et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
- (2015) Mario Tumbarello et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: A nationwide multicenter study in Taiwan
- (2015) Yea-Yuan Chang et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia
- (2015) Gul R. Yilmaz et al. Journal of Infection in Developing Countries
- Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: Molecular characterisation and treatment challenges
- (2015) Maria Katsiari et al. Journal of Global Antimicrobial Resistance
- Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
- (2015) Patrick N A Harris et al. Antimicrobial Resistance and Infection Control
- Extended-spectrum β-lactamase-producing Escherichia coli isolation among older adults: Epidemiology and outcomes
- (2014) Sameen Farooq et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
- (2014) Matthieu Boisson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
- (2014) Rujipas Sirijatuphat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
- (2014) George L. Daikos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and Safety Profile Comparison of Colistin and Tigecycline on the Extensively Drug Resistant Acinetobacter baumannii
- (2014) Sung Hee Kwon et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysis
- (2014) Yu-Chung Chuang et al. BMC INFECTIOUS DISEASES
- Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
- (2014) M. J. Siedner et al. CLINICAL INFECTIOUS DISEASES
- Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase–producing Proteus mirabilis
- (2014) Hsih-Yeh Tsai et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
- (2014) A. Batirel et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients
- (2014) M. P. Freire et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae
- (2014) B. Pilmis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia
- (2014) Thana Khawcharoenporn et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort
- (2014) L. E. Lopez-Cortes et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum -lactamase-producing Escherichia coli
- (2014) S. H. Park et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae
- (2014) M. Gonzalez-Padilla et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae
- (2014) D. van Duin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae
- (2014) Lisa M. Blanchette et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems
- (2013) Oren Zusman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains
- (2013) Jessica A. O'Hara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria
- (2013) Nicola Petrosillo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy and Safety of the Combination of Colistin plus Vancomycin for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
- (2013) José Garnacho-Montero et al. CHEMOTHERAPY
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
- (2013) Emanuele Durante-Mangoni et al. CLINICAL INFECTIOUS DISEASES
- The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
- (2013) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center
- (2013) Darowan S. Akajagbor et al. CLINICAL INFECTIOUS DISEASES
- Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options
- (2013) F. Kontopidou et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections
- (2013) Y.-T. Lee et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2013) G. Kalin et al. INFECTION
- Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria
- (2013) Konstantinos Pontikis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy
- (2013) Cheol-In Kang et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy
- (2013) Robbert Crusio et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections
- (2012) Kimberly Ku et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
- (2012) Zubair A. Qureshi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2012) Vicki L. Collins et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
- (2012) Teena Chopra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis
- (2012) Chih-Chao Yang et al. BMC INFECTIOUS DISEASES
- Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae: MIC Matters
- (2012) Nan-Yao Lee et al. CLINICAL INFECTIOUS DISEASES
- High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality
- (2012) A. Capone et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2012) H. AYDEMIR et al. EPIDEMIOLOGY AND INFECTION
- Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?
- (2012) H Gedik et al. Indian Journal of Medical Microbiology
- Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin
- (2012) Anucha Apisarnthanarak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes
- (2012) Joshua T. Freeman et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity
- (2012) Kelvin K.W. To et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
- (2012) Asako Doi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases
- (2012) D. E. Karageorgopoulos et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients
- (2012) Ryan K. Shields et al. PLoS One
- Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine
- (2011) Michael J. Satlin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
- (2011) J. Rodriguez-Bano et al. CLINICAL INFECTIOUS DISEASES
- Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment
- (2011) O. Zarkotou et al. CLINICAL MICROBIOLOGY AND INFECTION
- Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae
- (2011) Nan-Yao Lee et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pharmacokinetic and pharmacodynamic evaluation of tigecycline
- (2011) Helen Giamarellou et al. Expert Opinion on Drug Metabolism & Toxicology
- Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis
- (2011) Un-In Wu et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- The Outcomes of Using Colistin for Treating Multidrug Resistant Acinetobacter Species Bloodstream Infections
- (2011) Seung-Kwan Lim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality
- (2011) Alicia Hernández-Torres et al. MEDICINA CLINICA
- Infection withKlebsiella pneumoniaecarbapenemase (KPC)-producingK. pneumoniaein solid organ transplantation
- (2011) M.D. Bergamasco et al. Transplant Infectious Disease
- Bacteremia Due to Extended-Spectrum- -Lactamase-Producing Enterobacter cloacae: Role of Carbapenem Therapy
- (2010) C.-C. Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes
- (2010) May Nguyen et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
- (2010) Antonio T. Freire et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia
- (2010) Jeannie D. Chan et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
- (2009) Ronald Gounden et al. BMC INFECTIOUS DISEASES
- Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation
- (2009) A. Michalopoulos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
- (2009) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
- (2008) M. S. Oliveira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started